Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b Results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)

TEL AVIV, Israel, Feb. 18, 2025 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical [...]